Practice Test Geeks(MTM) Medication Therapy Management Certification for Pharmacists Practice Test
← All MTM Flashcard Decks

Respiratory Disease Management Flashcards

7 cards from real MTM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Respiratory Disease Management flashcards as text

  1. A patient's asthma is uncontrolled despite adherence to Step 3 therapy (low-dose ICS/LABA). Per GINA guidelines, what is the appropriate next step?

    Answer: Step up to medium-dose ICS/LABA

    GINA Step 4 involves increasing ICS dose while maintaining LABA, advancing from low-dose to medium-dose ICS/LABA combination therapy.

  2. Which inhaler device requires the LEAST patient coordination between actuation and inhalation?

    Answer: Nebulizer

    Nebulizers continuously convert liquid medication to fine mist, requiring minimal patient coordination and making them ideal for patients with poor inhaler technique.

  3. A COPD patient with blood eosinophils of 350 cells/μL continues to exacerbate frequently despite LABA/LAMA therapy. What is the most appropriate add-on treatment?

    Answer: Adding ICS to create LABA/LAMA/ICS triple therapy

    GOLD guidelines recommend adding ICS to LABA/LAMA (triple therapy) in COPD patients with eosinophils ≥300 cells/μL who continue to exacerbate on dual bronchodilation.

  4. A patient with severe persistent asthma requires antihypertensive therapy. Which antihypertensive class is CONTRAINDICATED due to risk of bronchospasm?

    Answer: Non-selective beta-blockers

    Non-selective beta-blockers block beta-2 receptors in bronchial smooth muscle, precipitating life-threatening bronchospasm in asthma patients.

  5. An MTM pharmacist reviews a patient's peak flow diary showing morning dipping greater than 20%. This finding is MOST consistent with which condition?

    Answer: Poorly controlled asthma

    Morning dipping in peak expiratory flow >20% (diurnal variation) is a hallmark of poorly controlled asthma reflecting significant airway variability.

  6. Roflumilast (Daliresp) is indicated as add-on therapy for which COPD patient population?

    Answer: Severe COPD with chronic bronchitis phenotype and frequent exacerbations

    Roflumilast, a PDE-4 inhibitor, is indicated for severe COPD patients with chronic bronchitis phenotype and ≥2 exacerbations per year despite standard therapy.

  7. A patient with exercise-induced bronchoconstriction (EIB) requests pre-exercise prophylaxis. Which recommendation is MOST appropriate?

    Answer: Inhaled SABA (albuterol) 15-30 minutes before exercise

    Inhaled SABA 15-30 minutes before exercise is the recommended prophylactic treatment for EIB due to its rapid onset and short duration of action.